Global Epoetin (Eritropoyetin) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Epoetin (Eritropoyetin) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Epoetin can be given intravenously or, more conveniently, subcutaneously, when a 25–50% lower dose can be used.
Epoetin (Eritropoyetin) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Epoetin (Eritropoyetin) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Anemia (Cancer and HIV Treatment) and Kidney Disorders (ESRD and Dialysis) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Epoetin (Eritropoyetin) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Epoetin (Eritropoyetin) key manufacturers include Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon and Intas Pharmaceuticals, etc. Amgen, Epoetin, Abcam are top 3 players and held % sales share in total in 2022.
Epoetin (Eritropoyetin) can be divided into Epoetin-alfa, Epoetin-beta and Darbepoetin Alfa,, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022.
Epoetin (Eritropoyetin) is widely used in various fields, such as Anemia (Cancer and HIV Treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound Healing),, etc. Anemia (Cancer and HIV Treatment) provides greatest supports to the Epoetin (Eritropoyetin) industry development. In 2022, global % sales of Epoetin (Eritropoyetin) went into Anemia (Cancer and HIV Treatment) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Epoetin (Eritropoyetin) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Epoetin
Abcam
Johnson & Johnson
Hospira Inc
Roche
LG Life Sciences Ltd
Biocon
Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Ranbaxy Laboratories Ltd
Celltrion, Inc
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin Alfa
Anemia (Cancer and HIV Treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound Healing)
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Epoetin (Eritropoyetin) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Epoetin (Eritropoyetin), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Epoetin (Eritropoyetin) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Epoetin (Eritropoyetin) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Epoetin (Eritropoyetin) introduction, etc. Epoetin (Eritropoyetin) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Epoetin (Eritropoyetin) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Epoetin (Eritropoyetin) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Epoetin (Eritropoyetin) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Anemia (Cancer and HIV Treatment) and Kidney Disorders (ESRD and Dialysis) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Epoetin (Eritropoyetin) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Epoetin (Eritropoyetin) key manufacturers include Amgen, Epoetin, Abcam, Johnson & Johnson, Hospira Inc, Roche, LG Life Sciences Ltd, Biocon and Intas Pharmaceuticals, etc. Amgen, Epoetin, Abcam are top 3 players and held % sales share in total in 2022.
Epoetin (Eritropoyetin) can be divided into Epoetin-alfa, Epoetin-beta and Darbepoetin Alfa,, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022.
Epoetin (Eritropoyetin) is widely used in various fields, such as Anemia (Cancer and HIV Treatment), Kidney Disorders (ESRD and Dialysis) and Others (Neural Disease and Wound Healing),, etc. Anemia (Cancer and HIV Treatment) provides greatest supports to the Epoetin (Eritropoyetin) industry development. In 2022, global % sales of Epoetin (Eritropoyetin) went into Anemia (Cancer and HIV Treatment) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Epoetin (Eritropoyetin) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Epoetin
Abcam
Johnson & Johnson
Hospira Inc
Roche
LG Life Sciences Ltd
Biocon
Intas Pharmaceuticals
Teva Pharmaceutical Industries Ltd
Ranbaxy Laboratories Ltd
Celltrion, Inc
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin Alfa
Segment by Application
Anemia (Cancer and HIV Treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound Healing)
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Epoetin (Eritropoyetin) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Epoetin (Eritropoyetin), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Epoetin (Eritropoyetin) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Epoetin (Eritropoyetin) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Epoetin (Eritropoyetin) introduction, etc. Epoetin (Eritropoyetin) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Epoetin (Eritropoyetin) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices